---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-219529"
form_type: "8-K"
ticker: "LBRX"
cik: "0001691082"
company_name: "LB PHARMACEUTICALS INC"
filed_at: "2026-05-12T20:21:01+00:00"
generated_at: "2026-05-12T20:24:25.449006+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# LB Pharma Q1 net loss $19.1M; cash $365.6M; Phase 3 schizophrenia trial launched

## Summary
- Net loss of $19.1M in Q1 2026 vs $5.3M in Q1 2025; R&D expenses rose $11.2M to $14.6M.
- Cash, equivalents, and marketable securities totaled $365.6M as of March 31, 2026; runway into Q2 2029.
- Initiated pivotal Phase 3 NOVA-2 trial of LB-102 in acute schizophrenia; topline data H2 2027.
- Phase 2 ILLUMINATE-1 trial in bipolar depression started Jan 2026; topline expected Q1 2028.
- Completed $100M private placement in Feb 2026; Phase 2 in adjunctive MDD planned early 2027.

## SEC filing metadata
- accession: 0001193125-26-219529
- form_type: 8-K
- ticker: LBRX
- cik: 0001691082
- company_name: LB PHARMACEUTICALS INC
- filed_at: 2026-05-12T20:21:01+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1691082/000119312526219529/0001193125-26-219529-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1691082/000119312526219529/d134118d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-219529
- JSON: https://secwatch.observer/filing/0001193125-26-219529.json
- Plain text: https://secwatch.observer/filing/0001193125-26-219529.txt

## Key facts
- Earnings Releases
  LB PHARMACEUTICALS INC reported financial results for the first quarter ended on March 31, 2026.
  - Period: the first quarter ended on March 31, 2026
  - Result: reported results
  source text: On May 12, 2026, LB Pharmaceuticals Inc (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2026.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1691082/000119312526219529/0001193125-26-219529-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.